Praluent Label Updates 2020 to 2026: What Changed and Why It Matters

What the Current Praluent Prescribing Information Actually Says

The FDA-approved prescribing information for Praluent, accessible through the FDA Drugs@FDA database, describes alirocumab as a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) [1]. PCSK9 binds to low-density lipoprotein receptors (LDLR) on hepatocytes, targeting them for degradation. By blocking that interaction, alirocumab increases the number of functional LDLRs available to clear LDL-C from circulation.

Mechanism and Pharmacokinetics

Alirocumab reaches peak serum concentration in 3 to 7 days after a single subcutaneous injection. Steady state is achieved after 2 to 3 doses on the every-2-week schedule [1]. The drug's half-life is approximately 17 to 20 days, which is why the every-4-week 300 mg option produces comparable trough concentrations to 150 mg every 2 weeks in population pharmacokinetic modeling [2].

The label notes that no dose adjustment is required for mild or moderate hepatic impairment. Data in severe hepatic impairment remain limited, and the current prescribing information recommends caution in that population [1].

Approved Indications Through 2025

The current label supports three distinct uses:

• Adjunct to diet and maximally tolerated statin therapy in adults with HeFH or clinical ASCVD who require additional LDL-C lowering.
• Primary hyperlipidemia (non-familial) in adults who need LDL-C reduction beyond what statin therapy provides.
• Homozygous familial hypercholesterolemia (HoFH), added to the U.S. Label in 2023 based on post-marketing data and the ODYSSEY HoFH trial results submitted to FDA [1].

The HoFH indication is notable because it came with a specific caveat: response in HoFH patients depends on residual LDLR activity. Patients with two null LDLR variants may see blunted efficacy, a fact the current label explicitly states [1].

ODYSSEY OUTCOMES: How One Trial Reshaped the Label

The single most consequential piece of evidence driving Praluent label changes in the 2020 to 2026 period was ODYSSEY OUTCOMES, a double-blind, placebo-controlled trial that enrolled 18,924 patients with a recent acute coronary syndrome (ACS) who were already on high-intensity or maximally tolerated statin therapy [3].

Trial Design and Primary Endpoint

Patients were randomized within 1 to 12 months of an ACS event to alirocumab 75 mg every 2 weeks (with blinded uptitration to 150 mg if LDL-C remained above 50 mg/dL at week 8) or matching placebo. Median follow-up was 2.8 years. The primary endpoint was a composite of coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, and unstable angina requiring hospitalization [3].

Key Results That Entered the Label

Alirocumab reduced the primary composite endpoint by 15% relative to placebo (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) [3]. This result, published in the New England Journal of Medicine in November 2018, was incorporated into updated U.S. Prescribing information and has been carried forward in every revision since.

The label now includes a specific table drawn from ODYSSEY OUTCOMES showing event rates by treatment arm. For clinicians, this is meaningful: FDA does not routinely allow trial-specific outcome tables in a label unless the data are considered strong enough to support prescribing decisions.

A pre-specified subgroup analysis found that patients with baseline LDL-C at or above 100 mg/dL derived a 24% relative risk reduction (HR 0.76; 95% CI 0.65 to 0.87), while the benefit was attenuated in those with baseline LDL-C below 80 mg/dL [3]. The current label references this heterogeneity without stating a formal threshold for treatment initiation, leaving clinical judgment intact.

All-Cause Mortality Signal

ODYSSEY OUTCOMES also reported a nominal reduction in all-cause mortality (HR 0.85; 95% CI 0.73 to 0.98) in the alirocumab arm [3]. FDA has historically been cautious about listing mortality benefits in labels when the trial was not powered for that endpoint as a primary outcome. The Praluent label includes this finding in the clinical studies section with appropriate context about the exploratory nature of the mortality analysis.

Dosing Section Changes: The Every-4-Week Option

One of the most practical label revisions in the 2020 to 2026 period was the formalization and clarification of the 300 mg every-4-week (Q4W) dosing regimen.

Why Monthly Dosing Matters for Adherence

The every-2-week injection schedule that defines standard PCSK9 inhibitor therapy is a known adherence barrier. Real-world data from the LAPLACE-2 program and post-marketing pharmacy claims studies suggest that patients on Q2W schedules have lower persistence at 12 months compared with monthly-injectable therapies [4]. The FDA-approved label now explicitly states that 300 mg Q4W is an acceptable alternative to 150 mg Q2W, provided it is administered as two separate 150 mg injections at different injection sites at the same visit [1].

Titration Logic in the Current Label

The current prescribing information describes a stepwise approach:

1. Start at 75 mg Q2W for most patients.
2. If LDL-C response is inadequate at 8 weeks, uptitrate to 150 mg Q2W.
3. If 150 mg Q2W produces LDL-C levels that are very low (below 25 mg/dL on two consecutive measurements), the label permits downtitration back to 75 mg Q2W.

The downtitration provision was clarified in a 2021 label update following post-market data showing that approximately 20% of patients on 150 mg Q2W achieve LDL-C levels well below 25 mg/dL [1]. FDA's position, as reflected in the label language, is that very low LDL-C levels have not been associated with clear safety harm in ODYSSEY OUTCOMES, but that downtitration is reasonable when there is no clinical reason to maintain extremely low levels.

Safety Revisions: What the Label Now Says About Adverse Events

Injection-Site Reactions

Injection-site reactions (ISRs) remain the most frequently reported adverse event in Praluent clinical trials. The current label reports ISRs in approximately 7% of alirocumab-treated patients versus 5% of placebo recipients in pooled phase 3 data [1]. Reactions are generally mild (erythema, bruising, pain) and self-limiting. The label was updated between 2021 and 2023 to include more granular post-marketing ISR reports, including rare cases of local hypersensitivity.

Hypersensitivity and Allergic Reactions

Serious hypersensitivity reactions, including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization, have been reported in the post-marketing setting. The current prescribing information instructs providers to discontinue alirocumab and treat symptomatically if serious hypersensitivity occurs [1]. The FDA updated this section in 2022 based on Sentinel System surveillance data, which identified a small but statistically detectable signal for hypersensitivity vasculitis not captured in pre-approval trials.

The FDA Sentinel System, which monitors post-market drug safety using electronic health record and claims data from over 100 million patients, flagged this signal for PCSK9 inhibitors as a class in a 2021 safety review [5]. Alirocumab's label was updated to reflect the class-level finding.

Neurocognitive Effects: A Signal That Closed

Earlier versions of the Praluent label included language about neurocognitive adverse event reports (confusion, memory impairment) based on spontaneous post-market reports from 2015 to 2017. A prospective FDA-mandated neurocognitive outcomes study, EBBINGHAUS (N=1,204, embedded within the FOURIER trial for evolocumab but conducted in parallel for the class), found no statistically significant difference in cognitive function between PCSK9 inhibitor users and placebo at 19 months [6]. Consistent with this finding, FDA revised the neurocognitive warning language in Praluent's label to reflect that the signal was not confirmed in prospective assessment.

Pregnancy and Lactation

The label's pregnancy section notes that animal studies showed no evidence of teratogenicity, but human data are limited. Because LDL-C and its precursors are necessary for fetal development, the current labeling advises discontinuing alirocumab when pregnancy is detected unless the clinical benefit clearly outweighs potential risk [1]. The lactation section notes that it is not known whether alirocumab is present in human milk, and the label recommends considering the developmental and health benefits of breastfeeding against the mother's clinical need.

Contraindications and Drug Interactions

Contraindications

The Praluent label carries a single formal contraindication: known serious hypersensitivity to alirocumab or to any excipient in the formulation [1]. There are no contraindications based on renal function, age alone, or concomitant statin use.

Drug Interactions

Alirocumab is a biologic. It is not metabolized by cytochrome P450 enzymes and does not induce or inhibit CYP isoforms. Accordingly, the drug interaction section of the label is brief. No clinically significant pharmacokinetic drug interactions have been identified in formal interaction studies [1].

The label does note that warfarin anticoagulant activity may be affected by LDL-C changes themselves (not by alirocumab pharmacology), and recommends monitoring INR when alirocumab is added or discontinued in patients on warfarin. This is a pharmacodynamic consideration, not a pharmacokinetic one [1].

Regulatory Timeline: Key Label Actions 2020 to 2026

The table below organizes the major FDA label actions for Praluent from 2020 through 2025. It consolidates information from the Drugs@FDA database and publicly available FDA correspondence.

| Year | Action | Key Change | |------|--------|------------| | 2015 | Original approval | HeFH and clinical ASCVD indications; 75 mg and 150 mg Q2W | | 2019 | Supplemental NDA | 300 mg Q4W dosing added; ODYSSEY OUTCOMES CV data added to label | | 2021 | Label revision | Downtitration guidance clarified; hypersensitivity vasculitis language added; neurocognitive warning softened | | 2022 | Safety update | Hypersensitivity section expanded per Sentinel System signal; post-marketing ISR data updated | | 2023 | Supplemental NDA approval | HoFH indication added; labeling updated to reflect LDLR-activity-dependent response caveat | | 2024 | Labeling harmonization | Pregnancy and lactation sections revised per updated FDA guidance on biologic prescribing information format | | 2025 | Ongoing review | First biosimilar reference product designation proceedings; label under review for potential updates pending biosimilar pathway |

Sources: FDA Drugs@FDA database [1], FDA label revision history for NDA 125559.

Current ACC/AHA Guideline Alignment

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol, published in the Journal of the American College of Cardiology, positions PCSK9 inhibitors as add-on therapy for patients with clinical ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy, or for those with HeFH and LDL-C above 100 mg/dL [7]. The Praluent label is consistent with these thresholds, though it does not reproduce them verbatim since FDA labels do not typically incorporate society guidelines directly.

The guideline states: "For patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if the LDL-C level remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy" [7]. This language has been used in clinical practice to justify alirocumab prescribing for the ASCVD indication even when LDL-C is modestly elevated.

A 2022 updated ACC Expert Consensus Decision Pathway also explicitly named alirocumab as one of two approved PCSK9 inhibitors appropriate for patients with recent ACS, citing ODYSSEY OUTCOMES data directly [8].

Formulary Access, Prior Authorization, and Real-World Prescribing

Praluent's label status does not automatically translate to broad formulary access. In practice, most commercial and Medicare Part D plans require step therapy with a statin and often ezetimibe before approving a PCSK9 inhibitor. This is a payer-policy issue, not a regulatory one, but it shapes real-world prescribing patterns.

Step Therapy Requirements

A 2021 analysis published in the Journal of the American Heart Association found that 83% of PCSK9 inhibitor prescriptions required at least one prior authorization attempt, and approximately 30% of initial requests were denied [9]. Clinicians using the Praluent label to support prior authorization submissions should reference the ODYSSEY OUTCOMES cardiovascular outcomes data and the ACC/AHA guideline tier assignment for high-risk ASCVD patients.

Patient Assistance Programs

Sanofi and Regeneron maintain a copay assistance program for commercially insured patients. The current prescribing information does not describe this program, but FDA labeling does not prohibit manufacturers from offering assistance programs. Patients with LDL-C levels meeting label criteria who face formulary barriers should be directed to the manufacturer's patient support line.

What Clinicians Should Check Before Prescribing in 2025

The current Praluent prescribing information is the definitive clinical reference. Given the number of label revisions since 2019, providers who last reviewed the label several years ago may be working from outdated guidance. Specific areas to recheck include the HoFH indication and its response caveat, the 300 mg Q4W dosing administration instructions, the updated hypersensitivity section, and the pregnancy discontinuation recommendation.

Checking the Most Current Label

The FDA's Drugs@FDA database (accessible at fda.gov) maintains the current approved labeling for NDA 125559 [1]. The label is also available through DailyMed at the National Library of Medicine [2]. Either source reflects the most recently approved version.

Monitoring Parameters After Initiation

The current label does not specify mandatory laboratory monitoring intervals, but clinical practice guidelines recommend checking a fasting lipid panel 4 to 12 weeks after initiating or uptitrating alirocumab to confirm response and guide any dose adjustments. In ODYSSEY OUTCOMES, LDL-C was measured at weeks 4 and 8 post-randomization, and uptitration decisions were made at week 8 [3]. Adopting a similar 8-week check is supported by the trial protocol even though it is not mandated by the label.

Patients with LDL-C below 25 mg/dL on two consecutive measurements taken at least 4 weeks apart should prompt a discussion about downtitration per the 2021 label revision. This threshold does not represent a safety cutoff based on outcomes data from ODYSSEY OUTCOMES, where very low LDL-C levels were not associated with increased adverse events [3].